At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 11-01 16:00:00 EDT
7.32
+0.11
+1.53%
盘后7.32
+0.000.00%
19:35 EDT
High7.37
Low7.16
Vol821.00K
Open7.20
D1 Closing7.21
Amplitude2.91%
Mkt Cap1.05B
Tradable Cap941.20M
Total Shares142.99M
T/O5.99M
T/O Rate0.64%
Tradable Shares128.58M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago
Aurinia Presents New Data Highlighting Real-World Utilization and Value of Lupkynis® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.